HPTN 052 is the name of a clinical trial conducted in nine countries which examined whether starting people living with HIV on antiretroviral therapy (ART) can reduce the chance that they will pass HIV on to their sexual partners who do not have HIV. The trial showed remarkable success in preventing HIV transmission and were so compelling that the study's Data and Safety Monitoring Board (DSMB) asked the research team to share the results with all study participants and offer ART to the control group (people who had been randomized to not start ART) before the study ended. As a result of the study there was increased consensus that treatment as prevention should be included as a public health strategy in lowering HIV infection. The trial was organized by the HIV Prevention Trials Network (
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - HPTN 052 (es)
- HPTN 052 (en)
|
rdfs:comment
| - HPTN 052 is the name of a clinical trial conducted in nine countries which examined whether starting people living with HIV on antiretroviral therapy (ART) can reduce the chance that they will pass HIV on to their sexual partners who do not have HIV. The trial showed remarkable success in preventing HIV transmission and were so compelling that the study's Data and Safety Monitoring Board (DSMB) asked the research team to share the results with all study participants and offer ART to the control group (people who had been randomized to not start ART) before the study ended. As a result of the study there was increased consensus that treatment as prevention should be included as a public health strategy in lowering HIV infection. The trial was organized by the HIV Prevention Trials Network ( (en)
- HPTN 052 es el nombre de un estudio clínico que examina hasta qué punto la terapia antirretroviral (TAR), al ser tomada por personas con VIH, puede disminuir el grado de infectividad y de ese modo reducir la probabilidad de transmitir el VIH a sus parejas heterosexuales. (es)
|
dct:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
has abstract
| - HPTN 052 es el nombre de un estudio clínico que examina hasta qué punto la terapia antirretroviral (TAR), al ser tomada por personas con VIH, puede disminuir el grado de infectividad y de ese modo reducir la probabilidad de transmitir el VIH a sus parejas heterosexuales. Los resultados del estudio fueron tan convincentes que el del estudio pidió al equipo de investigación que compartiera los resultados con todos los participantes del estudio y ofreciera la TAR al grupo de control antes de terminar el estudio. El estudio continúa para determinar si los resultados —que indican que la TAR reduce la transmisión del VIH en un 96%— tienen durabilidad. Este estudio fue organizado por la (HPTN). (es)
- HPTN 052 is the name of a clinical trial conducted in nine countries which examined whether starting people living with HIV on antiretroviral therapy (ART) can reduce the chance that they will pass HIV on to their sexual partners who do not have HIV. The trial showed remarkable success in preventing HIV transmission and were so compelling that the study's Data and Safety Monitoring Board (DSMB) asked the research team to share the results with all study participants and offer ART to the control group (people who had been randomized to not start ART) before the study ended. As a result of the study there was increased consensus that treatment as prevention should be included as a public health strategy in lowering HIV infection. The trial was organized by the HIV Prevention Trials Network (HPTN) and its chief architect was Myron S. Cohen. (en)
|
gold:hypernym
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is known for
of | |
is known for
of | |
is foaf:primaryTopic
of | |